Cytomed enters research collaboration agreement with Sengkang General

CytoMed Therapeutics announced that it has entered into a research collaboration agreement with Sengkang General Hospital Pte Ltd., a public hospital in Singapore and a member of the SingHealth Group. The two entities aim to establish a proof-of-concept for the use of an injectable cartilage regeneration therapy developed from donor-sourced umbilical cord-derived mesenchymal stem cells. This injectable therapy will undergo a proposed Phase I clinical trial, which is planned to take place in Singapore and is expected to be completed within two years. UC-MSCs are a form of stem cells that are isolated from the umbilical cord and possess the ability to self-renewal and differentiate into many cell types, such as bone, cartilage, fat, and muscle cells. They are also shown to modulate immune responses and inflammatory markers, making them ideal for application in regenerative medicine and immune-related disorders The global scientific community has recently seen increased interest in utilizing MSCs as a potential treatment for tissue regeneration, as well as inflammatory and regenerative diseases. The research collaboration announcement comes at a time when Singapore’s aging population sees an uptick in osteoarthritis of the knee, and will be in line to support healthcare initiatives for regenerative therapy.